🌐 Optimized English Content for SEO
The brain-computer interface (BCI) market encompasses hardware and software systems that enable Information interACTion and functional reconstruction between humans and external devices by decoding neural signals or stimulating the nervous system. This report covers three primary technical routes: Invasive (Implantable), Semi-invasive (Partially Implantable/ECoG), and Non-invasive (EEG/fNIRS/consumer wearables). The analysis includes medical rehabilitation, neuro-disease diagnosis/treatment, and consumer health APPlications.
The global BCI market was valued at approximately $1.49 billion in 2020. Driven by advancements in AI decoding algorithms and CLInical commercialization, the market is projected to reach $5.10 billion by 2030, reflecting a Compound Annual Growth Rate (CAGR) of roughly 13.9%. The period from 2025 to 2030 is identified as the primary acceleration window for clinical and commercial growth.
The Chinese BCI market dEMOnstrates high growth potential, driven by strong policy support and industrial expansion. Valued at approximately CNY 10 billion in 2020, the market is expected to surge to CNY 85.1 billion by 2030. A significant data leap is observed in 2024 (reaching CNY 32 billion), attributed to the inclusion of system integration solutions and the mass shipment of wearable devices.
By Technology: non-invasive BCI currently dominates the market (approx. 81.86% share in 2025) due to low cost and safety. However, Invasive and Semi-invasive technologies are gaining traction in high-value medical scenarios due to superior Signal-to-Noise Ratio (SNR) and bandwidth.
By Application: The Medical & Healthcare sector is the largest application, accounting for about 58.54% of the market in 2025. This includes stroke rehabilitation, spinal cord injury recovery, and Locked-In Syndrome communication.
Key Players:
Global: Neuralink (Invasive, PRIME trial), Synchron (Semi-invasive, Stentrode), Precision neuroscience (Semi-invasive, Layer 7), and Paradromics (Invasive).
China: Boruis (博睿康) (Semi-invasive, NEO system), Intelligent Brain (强脑科技) (Non-invasive, Wearables).
As of 2026, the industry has achieved significant regulatory milestones:
China: The National Medical Products Administration (NMPA) approved the world's first Invasive BCI medical device, Boruis's "Implantable BCI Hand Function Compensation System," in March 2026.
USA: Neuralink completed its Series E funding ($650M) and is conducting the PRIME clinical trial. Synchron is advancing its COMMAND study.
Ethics: Regulatory bodies (FDA, NMPA) and international organizations (UNESCO, OECD) are establishing Frameworks for neuro-rights, data privacy, and "Neurorights" governance.
The industry is shifting from "Hardware Sales" to "Hardware + Software + Data Services." Future growth will rely on cloud-based PaaS/SaaS platforms, long-term implant reliability, and the integration of Generative AI for neural decoding.
Comments & Questions (0)
No comments yet
Be the first to comment!